Here are some of the latest headlines from Wisconsin’s tech and innovation community: —Gov. Scott Walker signed a bill late Friday night that enacts statewide regulation of ridesharing services like Uber and Lyft. The bill had bipartisan support in the Legislature, but has drawn opposition by some Democratic legislators and city officials in Milwaukee and … Continue reading “Wisconsin Roundup: Uber Bill, Angel Deals, Exact Sciences, & More”
Tag: Exact Sciences
Wisconsin Roundup: Epic, Exact, Elli Health, StartupChicks, & More
Here is a collection of recent headlines in Wisconsin’s technology and innovation community: —Elli Health, a Delafield-based startup whose software enables virtual doctor visits, raised more than $774,000 from investors, a new SEC filing shows. The company previously raised $200,000 last year, according to an SEC document. —Madison-based AquaMost has raised more than $168,000 in … Continue reading “Wisconsin Roundup: Epic, Exact, Elli Health, StartupChicks, & More”
Exact Sciences’ Stock Stumbles on Early Cologuard Launch Data
Exact Sciences’ stock dipped on Tuesday after Wall Street got spooked by the company’s early sales results from the launch of Cologuard, its stool-based DNA test for colorectal cancer. Madison, WI-based Exact (NASDAQ: [[ticker:EXAS]]) saw its stock drop as much as 18 percent from its opening bell price yesterday of $24.86 per share, before closing … Continue reading “Exact Sciences’ Stock Stumbles on Early Cologuard Launch Data”
Wisconsin Roundup: Exact Sciences, Arrowhead, MCW, Marquette, & More
Here are some of the latest headlines from Wisconsin’s technology and innovation community: —Exact Sciences (NASDAQ: [[ticker:EXAS]]) could receive up to $9 million in state tax credits if it creates more than 750 jobs and invests $26 million in capital purchases here by 2020. The Madison-based company has been beefing up its staff after receiving … Continue reading “Wisconsin Roundup: Exact Sciences, Arrowhead, MCW, Marquette, & More”
Wisconsin Roundup: CDI, Exact, Centrose, ConjuGon, ConsortiEX, & More
Here are the latest headlines in Wisconsin’s tech and innovation community: —Madison-based Centrose raised $1 million in convertible debt that will help fund the salary of CEO James Prudent through 2019, according to a new SEC filing. The company is also raising equity investments through this funding round, which could eventually reach $21 million. Centrose … Continue reading “Wisconsin Roundup: CDI, Exact, Centrose, ConjuGon, ConsortiEX, & More”
Wisconsin Roundup: Exact Sciences, Walker Budget, WARF, & More
Here’s a recap of the latest headlines in Wisconsin technology and innovation: —Madison-based Exact Sciences (NASDAQ: [[ticker:EXAS]]) has gone on a hiring spree in the wake of securing approval in the U.S. and Europe for Cologuard, its stool-based DNA test for detecting colorectal cancer. The company has grown from 110 employees a year ago to … Continue reading “Wisconsin Roundup: Exact Sciences, Walker Budget, WARF, & More”
Wisconsin Roundup: Epic, Exact Sciences, Semba, Wicab, & More
With the holidays behind us, it’s time to catch up on some recent news in the world of Wisconsin technology and innovation: —Madison-based Semba Biosciences raised $511,175 from investors, according to a new SEC document. Investors have put at least $2.4 million into the company since it was founded in 2005, SEC documents show. Semba … Continue reading “Wisconsin Roundup: Epic, Exact Sciences, Semba, Wicab, & More”
Wisconsin Roundup: Zeon, Exact Sciences, Swoop Search, Isomark, & More
As everyone gets ready to enjoy time with family and friends, let’s take a moment to recap some of the big Wisconsin tech announcements in the days leading up to the holidays: —Milwaukee-based software services company Zeon Solutions was acquired by St. Louis-based Perficient for $35.7 million, the Milwaukee Business Journal reported. Most of Zeon’s … Continue reading “Wisconsin Roundup: Zeon, Exact Sciences, Swoop Search, Isomark, & More”
From Healthtech to Beer Tech, Xconomy Wisconsin’s 1st Year in Review
With 2014 coming to a close, it’s an appropriate time to reflect on the past year. That’s especially true for me today, as Xconomy celebrates the one-year anniversary of our launch in Wisconsin. It’s been an eventful 12 months, with plenty of big news—both exciting and discouraging developments for advocates of Wisconsin’s innovation and startup … Continue reading “From Healthtech to Beer Tech, Xconomy Wisconsin’s 1st Year in Review”
Exact Sciences Gets Medicare Reimbursement, Pursues Private Insurers
In another important step for Exact Sciences, the Madison, WI-based company said today that the Centers for Medicare & Medicaid Services (CMS) will reimburse the use of its colon cancer diagnostic at $502 per test. Exact’s (NASDAQ: [[ticker:EXAS]]) stock closed at $24.90 per share today, up more than 2 percent from yesterday’s close. CMS had … Continue reading “Exact Sciences Gets Medicare Reimbursement, Pursues Private Insurers”
Exact Sciences Execs Cash in on Colon Cancer Test’s Early Momentum
It’s been a good month for Exact Sciences and its top executives. With the Madison, WI-based company’s stock (NASDAQ: [[ticker:EXAS]]) trading near its all-time high, three executives and a board member cashed in significant chunks of their stock holdings earlier this month, earning them about $19.4 million total, according to SEC documents. In transactions from … Continue reading “Exact Sciences Execs Cash in on Colon Cancer Test’s Early Momentum”
Wisconsin Roundup: Exact Sciences, Epic, StartUp Health, & More
Here’s a rundown of recent important developments in Wisconsin’s tech and innovation community: —Shares of Madison-based Exact Sciences (NASDAQ: [[ticker:EXAS]]) shot up to a record $26.79 on Friday after it was announced that the company’s stool DNA test for detecting colorectal cancer, Cologuard, will be covered by Medicare. The stock closed last week at $24.60 … Continue reading “Wisconsin Roundup: Exact Sciences, Epic, StartUp Health, & More”
Wisconsin Roundup: Shoutlet, Exact Sciences, Echometrix, DuPont, & More
Here’s a quick rundown of recent notable announcements from Wisconsin’s innovation and tech community: —Group Health Cooperative of South Central Wisconsin became the first Wisconsin insurer to announce coverage of Madison-based Exact Sciences’ recently approved DNA-based screening test for colorectal cancer, Cologuard. Exact (NASDAQ: [[ticker:EXAS]]) is one of Madison’s more closely watched biotech companies right … Continue reading “Wisconsin Roundup: Shoutlet, Exact Sciences, Echometrix, DuPont, & More”
Wisconsin Roundup: Exact Sciences, CSA Partners, 100state, & More
In this week’s installment of Wisconsin innovation headlines, startups are raising capital, co-working spaces are on the move, and a closely watched Madison life sciences company offers details about initial commercialization of its FDA-approved product: —Cellectar Biosciences (NASDAQ: [[ticker:CLRB]]) raised $13.5 million in its first public offering since moving to the Nasdaq stock exchange from … Continue reading “Wisconsin Roundup: Exact Sciences, CSA Partners, 100state, & More”
For Exact Sciences, It’s Put Up or Shut Up Time For Colon Cancer Test
Exact Sciences CEO Kevin Conroy typically chooses his words carefully in interviews and public statements to investors, but he isn’t shy about making bold statements when it comes to the potential impact of his company’s newly-approved diagnostic test for colon cancer. “Cologuard may represent one of the most significant advancements in cancer screening in the … Continue reading “For Exact Sciences, It’s Put Up or Shut Up Time For Colon Cancer Test”
Exact Sciences’ Cologuard Approved Simultaneously by FDA, CMS
[Updated, 8/12/14, 8:13 a.m ET] The FDA approved Exact Sciences’ Cologuard test today, signing off on the first non-invasive, stool-based DNA screening test for colorectal cancer. The announcement isn’t a surprise, given the unanimous endorsement of the test in March by an FDA advisory panel that reviewed data from the company’s 10,000-patient clinical study. But … Continue reading “Exact Sciences’ Cologuard Approved Simultaneously by FDA, CMS”
Wisconsin Roundup: Exact Sciences, Bioforward, MCW, & More
A former Wisconsin governor has joined the board of promising Madison biotech company Exact Sciences. Meanwhile, there’s turnover at the top of the state’s biotech trade group. Read on for details about these announcements (and others) in this week’s rundown of Wisconsin innovation and technology headlines. —Jim Doyle, the Democrat who served as Wisconsin’s governor … Continue reading “Wisconsin Roundup: Exact Sciences, Bioforward, MCW, & More”
Wisconsin Roundup: Startup Weekend, Exact Sciences, 3D Printing
Last week was a busy one for Wisconsin’s tech and innovation community. Here are a few notable items you might have missed: —Madison, WI, held its third annual Startup Weekend, in which participants form teams and embark on a “54-hour frenzy of business model creation, coding, designing, and market validation.” Startup Weekend Madison judge Troy … Continue reading “Wisconsin Roundup: Startup Weekend, Exact Sciences, 3D Printing”
Dairyland Innovation: Xconomy Wisconsin’s Top Stories Since December Launch
It’s hard to believe, but it’s been just over three months since Xconomy launched in Wisconsin. Although it still doesn’t quite feel like spring in the Midwest, in the spirit of the (technically) new season, I thought it would be a good time to take a look back at the important stories Xconomy Wisconsin has … Continue reading “Dairyland Innovation: Xconomy Wisconsin’s Top Stories Since December Launch”
FDA Panel Gives Exact’s Colon Cancer Test Ringing Endorsement
It was all smiles and congratulatory handshakes for Exact Sciences president and CEO Kevin Conroy this afternoon after a panel of physicians and medical experts unanimously endorsed the Madison, WI-based company’s colon cancer screening test for FDA approval. The FDA advisory committee voted 10-0 on all three questions, indicating panelists’ belief that Cologuard—Exact’s non-invasive, stool … Continue reading “FDA Panel Gives Exact’s Colon Cancer Test Ringing Endorsement”
Exact Sciences’ Colon Cancer Test Clears Key Hurdle, FDA Next
Wall Street was pleased today with the newly published results of a pivotal study of Exact Sciences’ non-invasive screening test for colorectal cancer. Next step for the Madison, WI, company: FDA approval. Exact (NASDAQ: [[ticker:EXAS]]) announced top-line data of its 10,000-patient study in April 2013, but the full results were officially published Wednesday in a … Continue reading “Exact Sciences’ Colon Cancer Test Clears Key Hurdle, FDA Next”
Wisconsin Roundup: Startup Weekend, Epic Systems, Johnson Controls
A few notable news items from Wisconsin’s tech and innovation community over the last week: —The first Startup Weekend was held in the Green Bay area. About 45 people participated, forming nine startup teams in the span of 54 hours on St. Norbert College’s campus, said Chris Campbell, one of the volunteers who helped run … Continue reading “Wisconsin Roundup: Startup Weekend, Epic Systems, Johnson Controls”
Molecular Diagnostics Are in a Rut. The Industry Needs the FDA
Some of the more exciting ideas in biotech are coming up in molecular diagnostics. There’s cool science at work. A number of tests have potential to cut down on overtreatment, reduce waste in healthcare, and give physicians clever new ideas on how to help patients. But this industry, which accounts for less than 2 percent … Continue reading “Molecular Diagnostics Are in a Rut. The Industry Needs the FDA”
Exact Sciences, Once Near Death, Bounces Back With Colon Cancer Test
Four years ago, Exact Sciences was roadkill. The company, based in greater Boston at the time, had been experimenting with molecular diagnostic technologies for more than a dozen years. It had a stellar scientific pedigree from founder Stanley Lapidus. But it had burned through more than $170 million of investor cash, and still had no … Continue reading “Exact Sciences, Once Near Death, Bounces Back With Colon Cancer Test”
Xconomy Launches in Wisconsin: Innovation Isn’t Something We Fly Over
There are no flyover zones in the United States. That’s the way Xconomy views the map, anyway, because we see innovation happening all over America. So it is with great pleasure that today we are launching Xconomy Wisconsin, the ninth hub in our growing national network. It is our third launch this year—after Boulder-Denver and … Continue reading “Xconomy Launches in Wisconsin: Innovation Isn’t Something We Fly Over”
The Wisconsin Biotech Story: Slow and Steady Wins the Race
[Updated 1:04 pm PT] They say you can’t go home again. But sometimes you can go home after a few years and notice that your home has changed quite a bit. This past week, I went back to Wisconsin, where I’m originally from, to visit family and do some reporting. I stopped by the capitol, … Continue reading “The Wisconsin Biotech Story: Slow and Steady Wins the Race”
Follica Grabs $7.5M, Glaxo’s SR One Leads $22M Round For Constellation, MoMelan Seeks to Improve Skin Grafts, & More Boston-Area Life Sciences News
There were fewer life sciences headlines this week than we’ve seen lately, but the news covered an array of biotech companies fighting everything from baldness to skin disease to stubborn bacteria. —Watertown, MA-based Tetraphase Pharmaceuticals pulled in a $45 million Series C round that was led by new investor Excel Venture Management and also included … Continue reading “Follica Grabs $7.5M, Glaxo’s SR One Leads $22M Round For Constellation, MoMelan Seeks to Improve Skin Grafts, & More Boston-Area Life Sciences News”
$9M for SynapDx
Waltham, MA-based SynapDx,a developer of diagnostic technology for the early detection of autism, announced it has completed a $9 million Series A financing, with backing from Bain Capital, General Catalyst Partners, and North Bridge Venture Partners. The startup was founded by Stanley Lapidus, an entrepreneur known for starting life sciences companies such as Helicos BioSciences … Continue reading “$9M for SynapDx”
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten
New England has a deep pond with many of the very biggest fish in the global life sciences industry, but it also has its share of minnows, and they are getting eaten alive in the downturn. That finding leaped out at me after I scoured through financial data on 85 publicly traded life sciences companies … Continue reading “The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten”
Sequenom Maintains Tight Lid on “Mishandled Data” of Key Diagnostic Test
Three months ago, San Diego’s Sequenom disclosed that the launch of a new prenatal test for Down syndrome would be delayed because scientific data had been mishandled. So what have we learned since that bombshell announcement? Not much. The company’s recent quarterly filing with the SEC suggests Sequenom (NASDAQ: [[ticker:SQNM]]) must start the process of … Continue reading “Sequenom Maintains Tight Lid on “Mishandled Data” of Key Diagnostic Test”
Life Science Leaders Converge in Newport, PubGet Gets Your Paper Faster, I-Therapeutix Eyes $15M Prize & More Boston-Area Life Sciences News
Our Seattle compatriots have all arrived in Boston for XSITE. We wish we could say they brought the rain with them, but in fact, Boston has been far wetter than Seattle all month. The week’s life sciences news, however, isn’t quite the downpour you’ve all been dealing with outside. —Wide-roaming correspondent Ryan McBride took in … Continue reading “Life Science Leaders Converge in Newport, PubGet Gets Your Paper Faster, I-Therapeutix Eyes $15M Prize & More Boston-Area Life Sciences News”
Data Domain Fight Continues, Adimab Adds Merck and Roche as Partners, BigBelly Solar Gets Dirty With Waste Management, & More Boston-Area Deals News
[Corrected 4:40pm ET, June 22; see first item] Deals last week involved everything from cancer screening to trash compacting, but the analysts were kept on their toes by the dramatic events unfolding between EMC and Data Domain. —Reuters reported that data storage giant EMC (NYSE [[ticker:EMC]]), of Hopkinton, MA, was prepared to raise its bid—from … Continue reading “Data Domain Fight Continues, Adimab Adds Merck and Roche as Partners, BigBelly Solar Gets Dirty With Waste Management, & More Boston-Area Deals News”
Exact Sciences Moving to Wisconsin
Exact Sciences (NASDAQ:[[ticker:EXAS]]), a Marlborough, MA-based provider and developer of DNA tests for colorectal cancer, has garnered a $1 million loan from the state of Wisconsin and plans to relocate its headquarters from Massachusetts to Wisconsin, according to reports. News of the relocation comes three months after Exact announced that it had named a new … Continue reading “Exact Sciences Moving to Wisconsin”
Merck and Roche Back Adimab, Viral Contamination Closes Genzyme Plant, Interlace Ties on $20.5M, & More Boston-Area Life Sciences News
Three big pharmaceutical firms partnered with two New England life sciences companies this past week, and one ended a partnership. —Ryan learned that some 60 of the 240 people who were employed by Lexington, MA-based Indevus Pharmaceuticals when it was acquired for $370 million by Endo Pharmaceuticals in March will be laid off. Chadds Ford, … Continue reading “Merck and Roche Back Adimab, Viral Contamination Closes Genzyme Plant, Interlace Ties on $20.5M, & More Boston-Area Life Sciences News”
Exact Sciences Raises $8.2M
In a private placement of stock, Marlborough, MA-based Exact Science (NASDAQ: [[ticker:EXAS]]) has raised $8.2 in new funding, according to an announcement today. The company, which has developed a molecular screening test for colorectal cancer, also said it has licensed technology developed by cancer researcher David Ahlquist at the Mayo Clinic covering aspects of sample … Continue reading “Exact Sciences Raises $8.2M”
New Execs for Exact, Sirtris, and Ischemix; New Deal for Biogen and Aveo; New Money for MedAptus and Claros; & More Boston-Area Life Sciences News
The executive suites of several New England’s biotech and medical device companies saw new faces this week. —Cyberkinetics Neurotechnology Systems (OTC:[[ticker:CYKN]]), a Foxborough, MA-based developer of devices to treat and aid patients with spinal injuries, revealed to the Boston Globe that it is shutting down. Earlier this year Cyberkinetics sold the rights to its Andara … Continue reading “New Execs for Exact, Sirtris, and Ischemix; New Deal for Biogen and Aveo; New Money for MedAptus and Claros; & More Boston-Area Life Sciences News”
Charting Startups in the Downturn, San Diego’s Biotech Survival Index (Part Deux), Court Dismisses Federal Patent Suit Against Qualcomm, & More SD BizTech News
If there’s a theme to be found in the innovation news for San Diego last week, it might be comings and goings. While some companies are making layoffs or even shuttering their doors, we also found a number of new startups taking root here (although not as many as a year ago). —In a report … Continue reading “Charting Startups in the Downturn, San Diego’s Biotech Survival Index (Part Deux), Court Dismisses Federal Patent Suit Against Qualcomm, & More SD BizTech News”
After Fending Off Sequenom Takeover, Exact Sciences Replaces CEO and CFO with Diagnostics Vets
Exact Sciences, a Marlborough, MA, developer of a DNA-based stool test for detecting colorectal cancer, says that its board of directors has replaced the firm’s CEO and chief financial officer. The management changes follow the firm’s successful maneuvering to avoid a takeover by San Diego-based diagnostics firm Sequenom (NASDAQ:[[ticker:SQNM]]). The board of Marlborough, MA-based Exact … Continue reading “After Fending Off Sequenom Takeover, Exact Sciences Replaces CEO and CFO with Diagnostics Vets”
Biotech Survival Index 2: Boston Life Sciences Companies Squirrel Away More Cash for Long Winter
When I last crunched the numbers on the financial health of the Boston area’s public life sciences companies, back in November, I noted that 15 of them had more than $100 million stockpiled. These firms, I reasoned, were likely in a decent position to weather the economic storm. Now with quarterly financial reporting through December … Continue reading “Biotech Survival Index 2: Boston Life Sciences Companies Squirrel Away More Cash for Long Winter”
Harvard Researcher to Helm Merck’s Cancer Research, Genzyme Acquires Certain Exact Sciences Assets, NeurAxon Out to Axe Migraines, & More Boston-Area Life Sciences
New England life sciences firms gave us a little breather on the fast-breaking news this past week, so we had some time to take a closer look at some of the most interesting new companies and projects in the field. —Luke interviewed Tom Hughes, the CEO of Zafgen, and learned more about the startup’s plans … Continue reading “Harvard Researcher to Helm Merck’s Cancer Research, Genzyme Acquires Certain Exact Sciences Assets, NeurAxon Out to Axe Migraines, & More Boston-Area Life Sciences”
Exact Teams With Genzyme, Shrugs off Sequenom; Virtual Computer Reels in $15M; Beacon Power Inks National Grid Agreement; & More Boston-Area Deal News
Plenty of deals to discuss from all areas of technology and life sciences this week—including a couple of M&A switcheroos. —Diagnostics maker Exact Sciences (NASDAQ:[[ticker:EXAS]]) of Marlborough, MA, sold its assets related to prenatal and reproductive health to Cambridge, MA-based Genzyme (NASDAQ:[[ticker:GENZ]]) for $24.5 million. In response, San Diego-based Sequenom (NASDAQ:[[ticker:SQNM]]) ended its attempted takeover … Continue reading “Exact Teams With Genzyme, Shrugs off Sequenom; Virtual Computer Reels in $15M; Beacon Power Inks National Grid Agreement; & More Boston-Area Deal News”
Exact Sciences Takes $24.5M Genzyme Deal, Sequenom to Drop Buyout Offer
Exact Sciences, a diagnostics firm that had been running low on cash, has sold its assets related to prenatal and reproductive health to big biotech Genzyme for $24.5 million—prompting Sequenom to end its pursuit to buy Exact in an all-stock deal valued at $41 million, according to statements from Exact and Sequenom. Saying it could … Continue reading “Exact Sciences Takes $24.5M Genzyme Deal, Sequenom to Drop Buyout Offer”
Vertex Stays Put, Hydra Handed $22M, Sequenom Still Pursuing Exact Sciences Acquisition, & More Boston-Area Life Sciences News
[Corrected 1/21/09, see the item on Cynosure] The New England biomedical industry was on the quiet side this past week, but there are still a few tidbits to report. —California-based Sequenom (NASDAQ:[[ticker:SQNM]]) said it would press ahead with its effort to acquire Exact Sciences (NASDAQ:[[ticker:EXAS]]) even though the board of the Marlborough, MA-based diagnostics maker … Continue reading “Vertex Stays Put, Hydra Handed $22M, Sequenom Still Pursuing Exact Sciences Acquisition, & More Boston-Area Life Sciences News”
Medtronic Acquires Ablation Frontiers, Sequenom and Exact Sciences Go a Second Round, Qualcomm CEO Reflects on Strategy, & More San Diego BizTech News
It was like a real-world version of a TV game show in San Diego last week, with some companies announcing a “deal”—and some saying “no deal.” Let’s get on with the show: —Minnesota’s Medtronic (NYSE: [[ticker:MDT]]) gladdened the hearts of investors in Ablation Frontiers of Carlsbad, CA, by agreeing to pay $225 million upfront to … Continue reading “Medtronic Acquires Ablation Frontiers, Sequenom and Exact Sciences Go a Second Round, Qualcomm CEO Reflects on Strategy, & More San Diego BizTech News”
$55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News
Everything else around here is frozen solid this week (hello, minus two degrees real-feel!), but the tech and life sciences deals are flowing. —Two Massachusetts firms—Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) of Cambridge and Cubist Pharmaceuticals (NASDAQ: [[ticker:CBST]]) of Lexington—inked a marketing deal focused on Alnylam’s RNAi-based treatment for respiratory syncytial virus, or RSV. Under the terms … Continue reading “$55M for Boston-Power, Sequenom Plows Ahead with Exact Sciences Takeover Attempt, Nuance Announces $175M Stock Sale, & More Boston-Area Deals News”
Sequenom Getting Aggressive in Bid to Buy Exact Sciences
San Diego diagnostics firm Sequenom (NASDAQ:[[ticker:SQNM]]) says it plans to acquire all shares of cancer test maker Exact Sciences’ common stock (NASDAQ:[[ticker:EXAS]]), despite a rejection from Exact’s board of directors to Sequenom’s recent buyout offer. Sequenom proposes to buy each share of Marlborough, MA-based Exact for $1.50 worth of Sequenom common stock, a total value … Continue reading “Sequenom Getting Aggressive in Bid to Buy Exact Sciences”
Cubist and Alnylam Tackle RSV, Exact Sciences Fends Off Sequenom, An FDA Panel Backs GTC Biotherapeutics’ Goat-Milk Drug, & More Boston-Area Life Sciences News
New England’s life sciences firms unveiled some big deals and big plans this week. —Satori Pharmaceuticals raised $22 million from investors including InterWest Partners, Prospect Venture Partners, New Enterprise Associates, and PureTech Ventures (which launched the firm). The Cambridge, MA-based startup told Luke about its vision of becoming the first company to stop the progressive … Continue reading “Cubist and Alnylam Tackle RSV, Exact Sciences Fends Off Sequenom, An FDA Panel Backs GTC Biotherapeutics’ Goat-Milk Drug, & More Boston-Area Life Sciences News”
Exact Sciences to Sequenom: No Deal
Exact Sciences (NASDAQ:[[ticker:EXAS]]), a Marlborough, MA-based maker of cancer diagnostics, is searching for a better deal than the one it was offered last week by San Diego-based diagnostics firm Sequenom (NASDAQ:[[ticker:SQNM]]). This afternoon, Exact said its board of directors unanimously rejected Sequenom’s bid to acquire the company for $1.50 per share worth of Sequenom common … Continue reading “Exact Sciences to Sequenom: No Deal”
Sequenom Makes Takeover Bid for MA-Based Exact Sciences, Targets Test for Colorectal Cancer
San Diego-based Sequenom is flexing some of its newfound muscle, by making a takeover bid for Marlborough, MA-based Exact Sciences while it is on the ropes. Sequenom (NASDAQ: [[ticker:SQNM]]) said today after markets closed it is offering $1.50 worth of its own stock in exchange for each share in Exact Sciences (NASDAQ: [[ticker:EXAS]]). That values … Continue reading “Sequenom Makes Takeover Bid for MA-Based Exact Sciences, Targets Test for Colorectal Cancer”
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter
Boston is the biggest center of life sciences in the Xconomy network, and by our analysis, the Bay State’s biotech sector is also the best equipped to survive the economic crisis. I reached this conclusion by combing through public company filings of more than 70 life sciences companies in Boston, Seattle, and San Diego. For … Continue reading “Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter”